Summary: Sipoglitazar is a novel anti-diabetic agent with triple agonistic activities on the human peroxisome proliferator-activated receptors, hPPAR-£, -¡, and -¤. The bioavailability for sipoglitazar was 95.0% and 72.6% in rats and monkeys respectively and sipoglitazar is hardly subject to first pass metabolism in either species. Following oral administration of [
Introduction
The peroxisome proliferator-activated receptors ¤PPARs¥ are members of the nuclear receptor superfamily of ligandactivated transcription factors. Three PPAR subtypes have been identified so far, dubbed PPAR-AE, PPAR-È, and PPAR-É ¤also called PPAR-Ç¥. 1¥ PPAR-AE receptors are expressed primarily in the liver, play a critical role in lipid metabolism and are the target of the fibrate class of hypolipidemic drugs such as fenofibrate 2,3¥ and gemfibrozil. 4¥ PPAR-È receptors play a key role in energy storage, glucose homeostasis, and vascular biology. 5¥ Thiazolidinediones ¤TZDs¥ such as pioglitazone and rosiglitazone are known as typical agents to activate these receptors.
6,7¥ TZDs work via activation of PPAR-È; and activation of this receptor leads to increased insulin sensitivity in the liver, fat, and skeletal muscle cells. Although much less is known about the function of PPAR-É, its activation exerts beneficial effects on lipoprotein and glucose metabolism. 8¥ An attempt was made to develop sipoglitazar ¤TAK-654¥ as a novel anti-diabetic agent with triple agonistic activities on human PPAR-È, PPAR-AE, and PPAR-É, although the development was terminated ¤Fig. 1¥. Here we investigate the absorption, distribution, metabolism and excretion ¤ADME¥ profile of sipoglitazar in rats and monkeys. Animal studies using ª 14 C«sipoglitazar are essential to understand the fate of new drugs and these ADME data are helpful to understand the pharmacological properties of sipoglitazar, an activator for PPARs. Furthermore, to predict the metabolic profile and main excretion route from the body in humans, the in vitro metabolism of sipoglitazar was examined using human and animal hepatocytes and compared for their relationship in vivo and in vitro. These studies contribute to minimize negative effects from these species differences, which often have been a bottleneck problem in the development of new drugs. Sipoglitazar is a typical example to evaluate the non-clinical ADME properties before clinical studies, taking into account both the in vivo animal data and in vitro human data.
Methods
Chemicals: Sipoglitazar and its metabolites ¤M-I, 3-¤3-hydroxy-1-m4-ª¤2-phenyl-1,3-thiazol-4-yl¥methoxy«benzyln-1H-pyrazol-4-yl¥propanoic acid and M-II, 3-ª3-ethoxy-1-¤4-hydroxybenzyl¥-1H-pyrazol-4-yl«propanoic acid¥ were prepared by Takeda Pharmaceutical Company Limited ¤Osaka, Japan¥ ¤Fig. 1¥.
14 C-labeled sipoglitazar ¤ª 14 C«sipoglitazar¥ with a specific radioactivity of 4.58 MBq/mg was synthesized by Amersham Pharmacia Biotech UK Ltd. ¤Buckinghamshire, UK¥. The radiopurity ¤h98%¥ and chemical identity of the labeled compound were verified by thin-layer chromatography ¤TLC¥ and HPLC. All other reagents and chemicals were of the highest quality obtained from commercial suppliers such as Sigma-Aldrich ¤St. Louis, MO¥, ICN Pharmaceuticals, Inc. ¤Costa Mesa, CA¥, Ultrafine Chemicals ¤Manchester, UK¥, Oriental Yeast Co., Ltd. ¤Osaka, Japan¥, Dojindo ¤Kumamoto, Japan¥ and Wako Pure Chemical Industries, Ltd. ¤Osaka, Japan¥.
Administration of ª
14 C«sipoglitazar and collection of biological samples in rats and monkeys: A series of experiments were conducted to investigate the absorption, distribution, metabolism, and excretion of ª 14 C«sipoglitazar after single and multiple oral administrations to rats and monkeys. These studies were conducted according to protocols approved by Experimental Animal Ethical Committee at Takeda Pharmaceutical Company Limited ¤Osaka, Japan¥ and Nemoto Science Co., Ltd. ¤Ibaraki, Japan¥. The animals used in this study were male Crj: CD¤SD¥IGS rats ¤weight, 266 to 349 g; Charles River Japan Inc., Yokohama, Japan¥ and male cynomolgus monkeys ¤weight, 2.60 to 3.64 kg; Keari Co., Ltd., Osaka, Japan¥. They were fed laboratory chow ¤CR-LPF, Oriental Yeast Co., Ltd., Tokyo, Japan for the rats, and Monkey Bit, Nosan Corporation, Yokohama, Japan, or Primate Chow #5048, Purina Mills, Inc., St. Louis, MO for the monkeys¥, had free access to water, and were housed in temperature-and humidity-controlled rooms ¤20 to 26ôC and 40 to 70%¥ with 12-h light-dark cycles for more than one week before use. The applied dose was determined by considering the pharmacological dose and the detection limit of the radioactivity. ª 14 C«sipoglitazar, diluted appropriately with unlabeled compound, was suspended in a 0.5% ¤w/v¥ methylcellulose solution for oral ¤PO¥ or intraduodenal ¤ID¥ administration at a dose of 0.5 mg/10 mL/kg to the rats or 0.5 mg/2 mL/kg to the monkeys. ª 14 C«sipoglitazar was dissolved in a mixture of dimethyl acetamide and physiological saline ¤1:1, by volume¥ for intravenous ¤IV¥ injection at a dose of 0.5 mg/mL/kg to the rats or 0.5 mg/0.2 mL/kg to the monkeys. The vehicle used for IV injection, dimethyl acetamide, has been reported to cause some toxicity in animals and humans, but there were no harmful effects in this study. 9¥ The formulated sipoglitazar was administered to fed animals. After dosing, blood was taken from the tail vein or abdominal aorta at appropriate times in the rats or from the femoral vein in the monkeys. Urine and feces were collected in metabolic cages equipped with separators for urine and feces. Radioactive carbon dioxide in the expired air of the rats was absorbed in a mixture of methylcellosolve and monoethanolamine ¤2:1, by volume¥. Bile samples from the rats were obtained after cannulation of the common bile duct. In the enterohepatic circulation study, the collected bile was injected into the duodenum of other biliary-cannulated rats ¤10 mL/kg¥. After determination of the radioactivity, the samples were kept frozen at %20ôC until analysis.
Tissue distribution of ª 14 C«sipoglitazar in rats: To determine 14 C concentrations in the rat tissues, the following tissues were excised after a single oral dose of ª
14
C«sipoglitazar and after a once daily oral dose of ª 14 C«sipoglitazar for 21 days: blood, brain, spinal cord, hypophysis, eyes, Harderian glands, submaxillary glands, thyroid gland, thymus, heart, lungs, liver, spleen, pancreas, adrenals, kidneys, testes, skeletal muscle, skin, fat, brown fat, bone marrow, stomach and intestine. Identification and quantification of the metabolites in the biological samples from the rats and monkeys: ª 14 C«sipoglitazar and its metabolites in plasma, urine, feces, bile and tissues were quantified by TLC as follows. Plasma or aqueous homogenates of the feces were extracted with acetonitrile ¤5 vol.¥ and then the extracts were evaporated to dryness under a nitrogen gas stream at room temperature. The residues were dissolved in methanol. Then the solutions were subjected to TLC using plates precoated with silica gel 60F 254 ¤0.25-mm thick; E. Merck, Darmstadt, Germany¥, which were developed in dichloromethanemethanol ¤85:15, by vol.¥. The urine and bile samples were diluted with acetonitrile and put on TLC plates, which were then developed under the same conditions as described above. The component in the rat fat was also examined by alkaline hydrolysis and the same TLC analysis after extraction with acetone and ethylacetate. After development, the radioactive materials on the plate were located by radioluminography using a Bio-image Analyzer ¤BAS-2000II; Fuji Photo Film Co., Ltd., Tokyo, Japan¥ and imaging plate ¤BAS III; Fuji Photo Film Co., Ltd.¥ and by the UV-absorption of authentic sipoglitazar, M-I and M-II being added to the test samples as internal standards. The silica gel sections corresponding to sipoglitazar, M-I and M-II were scraped off the plate, the radioactivity in each section was counted and ª 14 C«sipoglitazar and its metabolites labeled with 14 C were identified by LC-MS/MS. The remaining material on the plates was also removed, counted, and referred to as úothers.û
For the measurement of the conjugated metabolites, portions of the urine, bile and aqueous homogenates of feces were incubated overnight at 37ôC with sulfatase of type H-1 ¤including Ç-glucuronidase activity, pH 5, Sigma-Aldrich¥. After incubation, 5 vol. of acetonitrile were added to the mixtures and the mixtures were centrifuged. The supernatants were analyzed in the same way as described above. Sipoglitazar-G and M-I-G were identified by LC-MS/MS and calculated by subtracting the unchanged values from the value of each fraction obtained by enzymatic treatment.
Structural analysis of sipoglitazar and its metabolites in the biological samples of rats and monkeys by LC-MS/MS: Sipoglitazar and M-I were extracted from the plasma of monkeys and M-II from the urine of rats as described above. The extracts were subjected to LC-MS/MS for analysis. The rat bile and monkey urine were directly subjected to LC-MS/MS for analysis of sipoglitazar-G and M-I-G, respectively. LC-MS and MS/MS analyses of the unchanged sipoglitazar, M-I, M-II, sipoglitazar-G and M-I-G were performed using HPLC ¤a Waters Alliance system with a Waters 2690 pump; Waters Assoc., Milford, MA¥ and an ion trap mass spectrometer ¤LCQ, Thermo Finnigan, San Jose, CA¥ equipped with an electrospray ionization ¤ESI¥ interface system. The HPLC conditions are described in úAnalytical procedures.û The spectra were obtained in the positive ion mode. The interface and mass spectrometer were operated under the following conditions: heated capillary temperature, 200ôC; spray voltage, 4.5 kV; sheath gas and auxiliary gas flow rate ¤arbitrary units¥, 80 and 15, respectively; and capillary voltage, 3.0 V. The collisionally induced dissociation ¤CID¥ fragment ions were generated using helium as a target gas, and the CID energy was 40%.
Measurement of the radioactivity:
The radioactivity in the biological samples, organic solvent extracts, silica gel from the TLC plates, and column effluent from the HPLC was determined with liquid scintillation counters ¤LSC-5100 and LSC-6100, Aloka Co., Ltd., Tokyo, Japan; LS-6000, Beckman Coulter, Inc., Brea, CA; and 2700TR, Packard Instrument Co., Inc., Downers Grove, IL¥ or flow scintillation analyzers ¤500TR, Packard Instrument Co., Inc., Meriden, CT¥. The radioactivity in each rat tissue and the feces was measured by the combustion method. All sample combustions were performed in a Sample Oxidizer from Packard Instrument Co. and the resulting 14 CO 2 was trapped in a mixture of Carbo-Sorb ¬ E ¤Packard¥ and Liquid scintillator B ¤Wako Pure Chemical Industries, Ltd.¥.
Pharmacokinetic analysis:
The half-life ¤t 1/2 ¥ in plasma for sipoglitazar was calculated by non-compartmental analysis using WinNonlin version 1.1 from Pharsight Corporation, Inc. ¤Mountain View, CA¥. The area under the plasma concentration-time curve ¤AUC¥ was calculated by the trapezoidal rule. The oral bioavailability of sipoglitazar was calculated by dividing the area under the curve ¤AUC 0®24h ¥ for sipoglitazar normalized by the oral dose molar equivalent of sipoglitazar by the AUC 0®24h for sipoglitazar normalized by the IV dose molar equivalent of sipoglitazar.
Incubation of ª
C«sipoglitazar with hepatocytes: Cryopreserved hepatocytes from rats, monkeys and humans ¤Celsis In Vitro Technologies, Baltimore, MD¥ were suspended using published procedures with minor modifications.
10,11¥ Hepatocytes, suspended in 0.5 mL of ice-cold Dulbeccoös Modified Eagle medium ¤DMEM¥ were dispensed onto 24-well culture plates at a density of 3 ' 10 5 viable cells/well, and 10 µmol/L of ª 14 C«sipoglitazar were incubated at 37ôC for 1, 2, 4 and 6 h. The reactions were terminated by the addition of a volume of acetonitrile equivalent to the volume of the reaction medium. After centrifugation at 1,500 ' g for 10 min, the supernatants were applied to the HPLC. The ratios of sipoglitazar and its metabolites were calculated, with the total radioactivity in the incubation mixture regarded as 100%. All incubations were made in duplicate.
Analytical procedures: ª 14 C«sipoglitazar and its metabolites in the samples for structural analysis and the in vitro study with hepatocytes were analyzed by HPLC. The supernatants were mainly analyzed by HPLC ¤LC-10 gradient system; Shimadzu Corp., Kyoto, Japan¥ with an on-line RI detector ¤D505TR Flow Scintillation Analyzer, Packard Instrument Company, Meriden, CT¥. The principal HPLC analytical method was as follows: The column was an Inertsil ODS-3 ¤5-µm particle size, 150 ' 4.6 mm or 250 ' 4.6 mm I.D.; GL Sciences, Tokyo, Japan¥. The mobile phase ¤A¥ ¤MP¤A¥¥ was H 2 O-acetonitrile-trifluoroacetic acid ¤TFA¥ ¤90:10:0.1, v/v¥ and the mobile phase ¤B¥ ¤MP¤B¥¥ was H 2 O-acetonitrile-TFA ¤10:90:0.1, v/v¥. The column temperature and the flow-rate were 40ôC and 0.5 or 1 mL/min. The scheduled program for the gradient elution was as follows: the concentration of MP¤B¥ was linearly increased from 30% to 70% over a period of 40 min, held at 95% for 10 min and then cycled back to the initial condition ¤30%¥. On-line RI detection was carried out using Ultima-Flo M as the flow scintillation cocktail.
Results
Apparent absorption ratio and bioavailability of ª 14 C«sipoglitazar after a single or repeated oral dose in rats and monkeys at a dose of 0.5 mg/kg: As calculated from the AUC ratios for 14 C after single oral and IV administration of ª 14 C«sipoglitazar, 95.1% and 80.3% of the orally dosed drug were apparently absorbed in rats and monkeys, respectively. The component of sipoglitazar was separated by TLC analysis using the same plasma samples and its concentrations were quantified. The maximum measured concentration of sipoglitazar in rat plasma was 1.172 µg/mL ¤Cmax¥ at 6.7 h ¤Tmax¥ after oral dosing with ª 14 C«sipoglitazar. The concentrations of sipoglitazar declined monophasically thereafter with an apparent half-life ¤t 1/2 ¥ of 6.5 h and AUC 0-24h of 16.88 µg&h/mL ¤Table 1 and Fig. 2A¥ . In monkeys given ª 14 C«sipoglitazar orally, the Tmax, Cmax, t 1/2AE , t 1/2Ç , and AUC 0-24h values for sipoglitazar were 1.1 h, 1.499 µg/mL, 2.5 h, 6.5 h and 6.99 µg&h/mL, respectively ¤Table 1 and Fig. 2B¥ . Based on the ratio of AUCpo and AUCiv, the bioavailability of sipoglitazar was calculated to be 95.0% and 72.6% in rats and monkeys respectively, showing the high bioavailability in both species. During repeated oral administration of ª 14 C«sipoglitazar to rats for 14 days, the pharmacokinetic behavior of 14 C in the plasma hardly changed ¤Table 2¥.
Distribution of ª
14 C«sipoglitazar and its related compounds:
The 14 C concentrations in the tissues were examined at 2, 4, 8, 24, 72, 120 and 168 h after a single oral administration of ª 14 C«sipoglitazar to the rats ¤Fig. 3¥. In most tissues, 14 C was maximal at 4 h after dosing ¤0.5 mg/kg¥. At 4 h, the concentration of 14 C was the highest in the liver, followed in decreasing order by the plasma, Harderian glands, blood, intestine, kidneys, brown fat, adrenals, lungs, heart, skin, hypophysis, thyroid gland, submaxillary glands, pancreas, stomach, testes, bone marrow, spleen, thymus, fat, skeletal muscle and eyes; it was lowest in the spinal cord and brain. Although the elimination of 14 C in the adrenals, fat and brown fat was relatively slow, the 14 C in most other tissues then decreased to very low concentrations within 168 h.
On repeated oral dosing of ª 14 C«sipoglitazar ¤0.5 mg/kg¥ to rats for 21 days, the concentrations of 14 C in most tissues increased gradually and attained steady state within 21 days ¤data not shown¥. After the 21st dose, the 14 C concentration was the highest in the brown fat, followed in decreasing order by the fat, adrenals and skin and thereafter 14 C in most tissues except for these adipose tissues decreased to low concentrations within 28 days. Especially in the fat, although elimination of 14 C was observed, its rate was much slower than that in the other tissues ¤Fig. 4¥. A major component of 14 C in the fat was elucidated to be sipoglitazar as esterconjugates by alkaline hydrolysis after extraction with acetone and ethylacetate ¤data not shown¥.
In vivo metabolic profiles of plasma and excreta of rats and monkeys given a single oral dose of ª
14
C«sipoglitazar at a dose of 0.5 mg/kg: From the AUC 0-24h values calculated by the composition analysis of the plasma, 96.2% and 62.1% of the total 14 C were accounted for by sipoglitazar in the rats and monkeys, respectively ¤Table 3¥. Small amounts of M-I and M-II were also detected in the plasma of both species, but the glucuronides of sipoglitazar and M-I were not detected. The other components in the plasma were minor and summarized as others. In the excreta of the rats and monkeys, various metabolites were detected ¤Table 4¥. Over 48 h after administration of ª 14 C«sipoglitazar to the rats, 3.3% and 88.1% of the total 14 C were excreted in the urine and feces and the main component was M-II in the urine and sipoglitazar containing unabsorbed drug in the feces, respectively. In rat bile, 83.6% of the total 14 C was recovered in 24 h after administration and 56.1% of the 14 C were excreted in the urine and feces and the main component was M-I-G in the urine and M-I in the feces, respectively. Therefore, sipoglitazar was metabolized to M-I, M-II, sipoglitazar-G, M-I-G and other unidentified metabolites with high polarity in the rats and monkeys.
In vitro metabolic profiles of ª 14 C«sipoglitazar with hepatocytes of humans, rats and monkeys: The in vitro metabolism of ª 14 C«sipoglitazar was studied using hepatocytes from rats, monkeys and humans ¤Fig. 5¥. In human hepatocytes, sipoglitazar was metabolized to M-I, M-II, sipoglitazar-G and unidentified metabolites ¤UK-A, -B, -C, -D and -E¥. The concentration of each metabolite in human hepatocytes increased with incubation time and some metabolites attained saturation at 6 h ¤Fig. 5A¥. The composition ratios of sipoglitazar, M-I and sipoglitazar-G were 44.9%, 19.0% and 17.9%, respectively, and these two metabolites were the major ones in the human hepatocytes incubated for 6 h ¤Fig. 5B¥. In rat hepatocytes, sipoglitazar was the main component and M-I, M-II, sipoglitazar-G were also detected, although the amount formed was very limited. In monkey hepatocytes incubated for 6 h, the composition ratios of sipoglitazar, M-I and sipoglitazar-G were 35.4%, 8.2% and 29.6%, respectively. The metabolic profile with the monkey hepatocytes was similar to that with humans and there was no metabolite specific for humans.
Structural analysis of sipoglitazar and its metabolites: The structural analysis of M-I, M-II, sipoglitazar-G and M-I-G was confirmed by LC-MS/MS. For M-I and M-II, their mass spectral data and the HPLC retention time were in good agreement with those of the authentic compounds.
The full ion mass spectrum of sipoglitazar-G gave the ªM¦H« ¦ at m/z 642, which was 176 amu higher than that of sipoglitazar. The characteristic fragment ions in the product ion mass spectrum at m/z 642 were detected at m/z 624, 282 and 174. The ion at m/z 624 was a dehydrated ion. The ions at m/z 282 and 174 were the same as those of sipoglitazar. Alkaline hydrolysis ¤0.1 mol/L sodium hydroxide solution, at 37ôC for 2 h¥ and enzymatic hydrolysis ¤5 w/v% of sulfatase containing Ç-glucuronidase ¤type H-1¥, at 37ôC for 2 h¥ of the peak at m/z 642 of sipoglitazar-G gave sipoglitazar in the LC-MS.
The full ion mass spectrum of M-I-G gave the ªM¦H« ¦ at m/z 614, which was 176 amu higher than that of M-I. The characteristic fragment ions in the product ion mass spectrum at m/z 614 were detected at m/z 438 and 282. The ions at m/z 438 and 282 were derived by diagnostic loss of the sugar moiety ¤%176 amu¥ and were the same as that of M-I. Sipoglitazar-G Although M-I was not obtained by alkaline hydrolysis, enzymatic hydrolysis ¤5 w/v% of sulfatase containing Ç-glucuronidase ¤type H-1¥, 37ôC, 14 h¥ of its peak gave M-I.
Cumulative excretion of 14 C in the urine, feces, and bile of rats and monkeys given a single oral dose of ª
C«sipoglitazar at a dose of 0.5 mg/kg: Following oral administration of ª 14 C«sipoglitazar to the rats, most of the radioactivity was recovered within 96 h, with 3.4% and 92.3% of the dose appearing in the urine and feces, respectively and less than 0.1% of the dose excreted in expired air ¤Table 5¥. In monkeys, 36.6% and 55.5% of the orally administered radioactivity were excreted in the urine and feces within 168 h, respectively ¤Table 5¥. The dosed 14 C was largely excreted into the feces in rats and was excreted in both urine and feces in monkeys.
In biliary-cannulated rats given ª 14 C«sipoglitazar intraduodenally, 83.6% of the administered radioactivity was excreted in the bile over 24 h ¤Tables 4 and 5¥. Within 24 h after ID administration of the radioactive bile to other biliary-cannulated rats, 66.9% and 1.3% of the dosed radioactivity were excreted in bile and urine, respectively. It is thus evident that the major part of biliary radioactivity undergoes enterohepatic circulation in rats.
Discussion
To examine the fate of sipoglitazar in experimental animals, the absorption, distribution, metabolism and excretion of the radioactivity and sipoglitazar were investigated in rats and monkeys after single or multiple administration of ª 14 C«sipoglitazar. Furthermore, in vitro metabolism of sipoglitazar was also examined using human and animal hepatocytes. By comparing their relationship in vivo and in vitro, the metabolic profile and the main excretion route from the body in humans could be presumed.
Sipoglitazar exhibited good oral absorption and bioavailability in both species and the apparent absorption ratios and bioavailability showed similar values ¤Table 1 and Fig. 2¥ . Sipoglitazar accounted for a major part of the radioactivity in the plasma of both species ¤Table 3¥. These findings indicated that sipoglitazar was significantly absorbed without first pass metabolism. With repeated oral administration of ª 14 C«sipoglitazar to rats for 14 days, the pharmacokinetic parameters remained generally unchanged ¤Table 2¥. This property would be helpful for the dosing plan of sipoglitazar in humans to control the plasma concentrations safely.
Absorbed sipoglitazar and its metabolites were distributed in rat tissues with relatively high concentrations in the liver after a single oral administration, resulting in the metabolic stimulation of sipoglitazar ¤Fig. 3¥. The distribution of ª 14 C«sipoglitazar after single administration was also observed in the target tissues of PPAR-È, skeletal muscle and adipose tissue, although their distributed concentrations were low. The concentrations of 14 C in adipose tissues remained relatively high after multiple administrations, although 14 C was gradually excreted from almost all the tissues ¤Fig. 4¥. The main component of 14 C for the fat, one of the target tissues to activate PPAR-È, was elucidated to be sipoglitazar by alkaline hydrolysis and the same as that for the plasma in rats. These results indicated that the main component could be the same for all the tissues in rats and the pharmacologically active substance sipoglitazar was distributed to the target tissues, in which PPAR-AE and PPAR-È are predominantly expressed. 1¥ Furthermore, sipoglitazar was considered to exist as an ester-conjugate with the triglyceride of fatty acids in the fat, because alkaline hydrolysis could elucidate the component in the fat, while only liquid-liquid extraction with organic solvents like acetone or ethylacetate could not yield sipoglitazar in the fat, probably due to the endogenous fatty acids. Thus, the fatty acids with triglyceride in the fat could play an important role in retaining sipoglitazar in the tissues. The rapid elimination of 14 C from skeletal muscle, one of the target tissues to activate PPAR-È, was likely due to the low level of fatty acids. Considering these results in total, sipoglitazar is stored as the ester-form in the fat after multiple administrations, released into the plasma gradually by hydrolysis and thus contributes to the action on the PPARs. Adipose PPAR especially would work as an essential mediator for the maintenance of whole body insulin sensitivity. 12¥ This could be consistent with the pharmacological results that sipoglitazar enhanced glucose uptake in white adipose tissue of Wistar fatty rats administered sipoglitazar ¤1.2 mg/kg/ day¥ repeatedly for 7 days and after the final administration on day 7, its effect was maintained even on day 8 ¤M. Matsumoto, personal communications¥. These results indirectly indicate that the distribution properties of sipoglitazar contribute to the duration of the pharmacological effects.
Sipoglitazar was metabolized to M-I, M-II, their glucuronide conjugates ¤sipoglitazar-G and M-I-G¥, and unidentified metabolites in rats and monkeys and these identified metabolites could account for the major part of the metabolic profile in rats and monkeys ¤Tables 3 and 4¥. The larger formation amount of M-I and others in monkeys than that in rats indicates that the metabolism of sipoglitazar in monkeys is more extensive than in rats ¤Table 3¥. Moreover, there was an apparent difference between rats and monkeys in the metabolic profile in the excreta ¤Table 4¥. In rats after single oral administration of ª 14 C«sipoglitazar, the dosed 14 C was largely excreted in the feces and the major component was sipoglitazar, while the minor components sipoglitazar-G, M-I and M-II were also detected ¤Tables 4 and 5¥. In biliary cannulated rats given ª 14 C«sipoglitazar intraduodenally, 83.6% of the dose was excreted in the bile and the major part of biliary radioactivity underwent enterohepatic circulation ¤Tables 4 and 5¥. Thus, sipoglitazar and its metabolites were eliminated via biliary excretion into the feces in rats and sipoglitazar-G was a key metabolite. In monkeys, the excretion route was via both the urine and feces and the major component was M-I-G in the urine and M-I in the feces, indicating that the metabolic pathway from M-I to M-I-G was very important ¤Tables 4 and 5¥. The excretion ratio in urine was significantly higher in the monkeys than in rats, which might be due to the enhanced metabolism from M-I to the more water-soluble M-I-G in monkeys. These results indicated that the important metabolite in the metabolic profile of sipoglitazar was sipoglitazar-G in rats and M-I and M-I-G in monkeys. However, the involvement of sipoglitazar-G as the excretion route in monkeys could not be denied, because sipoglitazar-G could be also observed as a minor metabolite in the excreta of monkeys. On the other hand, the in vitro metabolism with hepatocytes of humans and animals showed that the metabolism of sipoglitazar in humans appeared to be similar with that in the monkeys and there was no metabolite specific for humans ¤Fig. 5B¥. Considering that there was a good correlation for the oxidative metabolites between the feces and hepatocytes of rats and monkeys, M-I was a key metabolite in the elimination process in humans in vivo. Meanwhile, there was little correlation for the glucuronidation between the excreta and hepatocytes of animals. The sipoglitazar-G formation was limited in the rat hepatocytes and excreta, but actually sipoglitazar was shown to be excreted via biliary excretion as sipoglitazar-G in rats ¤Table 4 and Fig. 5B¥ . These differences probably come from two reasons; one is the enterohepatic circulation of sipoglitazar-G in vivo and the other is the unstable properties of sipoglitazar-G in the medium with neutral pH in vitro, which is reported as the acyl migration and degradation of the glucuronides.
13,14¥ These will cause the discrepancy between the in vitro and in vivo studies. Furthermore, sipoglitazar-G was formed in the hepatocytes of humans and monkeys more extensively than in rats. Considering these results in total, glucuronidation of sipoglitazar could be also presumed to be an important elimination route in humans and monkeys. Moreover, the glucuronidation of M-I was presumed to occur in humans from the high composition ratio of M-I-G in monkey urine.
In conclusion, sipoglitazar has no fatal non-clinical ADME profile for clinical evaluation. The compound exhibits good oral absorption and bioavailability in rats and monkeys, distribution to target tissues such as fat and excretion. The main component in the plasma of rats and monkeys dosed with sipoglitazar was the parent compound. In rats, sipoglitazar was mainly excreted into the feces via biliary excretion as sipoglitazar-G, while the major component was M-I-G in the urine and M-I in the feces of monkeys. Comparing the metabolic profiles in the hepatocytes, the metabolism of sipoglitazar in monkeys rather than that in rats would be more helpful in understanding that in humans and the formation of M-I was considered to be crucial in humans. Moreover, glucuronidation was also presumed to be an important excretion route in humans from the biliary excretion as sipoglitazar-G in rats and the high composition ratio of M-I-G in monkey urine. These results suggest that sipoglitazar will be cleared primarily by oxidation and glucuronidation in humans. Further investigation of the biotransformation of sipoglitazar is also necessary.
